Chmiela Tomasz, Rzepka Michalina, Kuca Maciej, Serwońska Karolina, Laskowski Maciej, Koperczak Agnieszka, Siuda Joanna
Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.
Students' Scientific Association, Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.
Life (Basel). 2022 Jul 17;12(7):1068. doi: 10.3390/life12071068.
COVID-19 has affected the entire world and has had a great impact on healthcare, influencing the treatment of patients with acute ischemic stroke (AIS). The aim of this study was to determine the impact of the COVID-19 pandemic on the care of patients with AIS. We performed a retrospective analysis of 1599 patients diagnosed with AIS and hospitalized in the authors' institution from January 2018 to December 2021. The final sample consisted of 265 patients treated with thrombolysis without a diagnosis of COVID-19. The initiation of thrombolytic treatment during the pandemic was delayed (2:42 ± 0:51 vs. 2:25 ± 0:53; = 0.0006). The delay was mainly related to the pre-hospital phase (1:41 ± 0:48 vs. 1:26 ± 0:49; = 0.0014), and the door-to-needle time was not affected. There were no differences in stroke severity and patients' outcomes. Patients with AIS were less likely to have previously been diagnosed with atrial fibrillation (16.9% vs. 26.7%; = 0.0383), ischemic heart disease (25.3% vs. 46.5%; = 0.0003) and hyperlipidemia (31.2% vs. 46.5%; = 0.0264). Patients treated during the pandemic had higher glycemia (149.45 ± 54. vs. 143.25 ± 60.71 mg/dL; = 0.0012), while no significant differences in their lipid profiles were found. Conclusions: The COVID-19 pandemic affected the treatment of AIS patients locally at our stroke center. It caused treatment delay and hindered the recognition of risk factors prior to the occurrence of AIS.
新型冠状病毒肺炎（COVID-19）已影响全球，并对医疗保健产生了重大影响，进而影响急性缺血性脑卒中（AIS）患者的治疗。本研究的目的是确定COVID-19大流行对AIS患者护理的影响。我们对2018年1月至2021年12月在作者所在机构诊断为AIS并住院的1599例患者进行了回顾性分析。最终样本包括265例接受溶栓治疗且未诊断为COVID-19的患者。大流行期间溶栓治疗的启动延迟（2:42±0:51对2:25±0:53；P = 0.0006）。延迟主要与院前阶段有关（1:41±0:48对1:26±0:49；P = 0.0014），而门到针时间未受影响。卒中严重程度和患者预后无差异。AIS患者先前被诊断为房颤的可能性较小（16.9%对26.7%；P = 0.0383），缺血性心脏病（25.3%对46.5%；P = 0.0003）和高脂血症（31.2%对46.5%；P = 0.0264）。大流行期间接受治疗的患者血糖较高（149.45±54.对143.25±60.71mg/dL；P = 0.0012），而血脂谱无显著差异。结论：COVID-19大流行在我们的卒中中心对AIS患者的治疗产生了局部影响。它导致治疗延迟，并阻碍了AIS发生前危险因素的识别。
